In About Face, Gilead Asks FDA To Rescind Remdesivir’s Rare Drug Status

By Beth Wang / March 25, 2020 at 8:04 PM
Gilead on Wednesday (March 25) requested that FDA rescind orphan drug designation for the company’s investigational antiviral drug remdesivir after an outcry from public health consumer advocates who argued the designation would allow Gilead to benefit from market exclusivity and tax incentives that could cut out competition and raise prices for patients. In a press statement, the company says FDA can review remdesivir just as fast without the designation. On Monday (March 23), FDA granted orphan drug designation to remdesivir,...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.